Nine Diagnostics Joins Damon Runyon Cancer Research Foundation InVEST Program
Freddy Nguyen Featured on Pitt HexAI Podcast for Precision Medicine Innovation
Freddy Nguyen Featured on From Models to Medicine for Diagnostic AI Equity
Nine Diagnostics Joins DRIVE Accelerator with SCbio and MassBio
Nine Diagnostics Pitches at BioTools Innovator East Coast Road Tour
Industrial Adoption of Carbon Nanotubes — Nano Letters
Nine Diagnostics Selected to Present at FNIH Biomarkers Consortium 20th Anniversary Symposium
Freddy Nguyen Featured in The Scientist on NSF Tech Labs Initiative
Heller and Kim Selected for ARPA-H LIGHT Program on Lymphatic Disease Diagnostics
Nine Diagnostics and Orbits Oncology Launch Exploratory Partnership on Precision Oncology Platform
Nanosensor Liquid Biopsy Detects and Classifies Brain Tumors — Nature Nanotechnology
Nine Diagnostics Graduates from ACS BrightEdge Entrepreneurs Program
Daniel Heller Featured on KVIA-TV ABC-7 for Nanosensor Ovarian Cancer Detection Research
Nine Diagnostics Selected for Medical Alley Q3 Innovation Showcase
Nine Diagnostics Selected for Second Annual Boston Biotech Investor Day
Nine Diagnostics Wins Runner-Up at RESI Boston Longevity Competition
Nine Diagnostics Co-Founder Daniel Heller in Women’s Health Magazine
Building a Measurement Science Startup — Applied Spectroscopy Practica
Nine Diagnostics CEO Freddy Nguyen Named 2025 National Academy of Medicine Scholar in Diagnostics
Nine Diagnostics CEO Freddy Nguyen at MIT Health Science Forum 2025
The Definitive Reference on Carbon Nanotubes in Biomedicine — Handbook of Carbon Nanomaterials
Nine Diagnostics Joins ACS BrightEdge Entrepreneurs Program
Nine Diagnostics Co-Founder Daniel Heller Featured in BBC News
Nine Diagnostics Joins U.S.-Dutch Consortium for Women’s Health Diagnostics
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3
Nine Diagnostics Selected for Inaugural CancerHackerLab Accelerator Cohort
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency
Nine Diagnostics Selected to Participate in The Engine’s Blueprint Program
Nine Diagnostics Selected to Participate in NSF I-Corps Program at MIT
Nine Diagnostics Founded to Advance AI-Enabled Nanosensor Diagnostics
Daniel Heller Featured on NBC New York for AI-Enabled Ovarian Cancer Blood Test Research
Mijin Kim Named a 2023 STAT Wunderkind for Nanosensor Cancer Detection Research
Mijin Kim Named a 2022 MIT Technology Review Innovator Under 35
Nanosensor Liquid Biopsy Detects Ovarian Cancer with 87% Sensitivity — Nature Biomedical Engineering
